SynAct Pharma Dirección

Dirección controles de criterios 0/4

El CEO de SynAct Pharma's es Jeppe Ovlesen , nombrado en Mar 2024, tiene una permanencia de menos de un año. compensación anual total es SEK3.66M, compuesta por 91% salario y 9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.039% de las acciones de la empresa, por valor de SEK103.56K. La antigüedad media del equipo directivo y de la junta directiva es de 0.8 años y 0.1 años, respectivamente.

Información clave

Jeppe Ovlesen

Chief Executive Officer (CEO)

kr3.7m

Compensación total

Porcentaje del salario del CEO	91.0%
Permanencia del CEO	less than a year
Participación del CEO	0.03%
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	less than a year

Actualizaciones recientes de la dirección

Recent updates

Here's Why We're Watching SynAct Pharma's (STO:SYNACT) Cash Burn Situation

Sep 04

Is SynAct Pharma (NGM:SYNACT) In A Good Position To Deliver On Growth Plans?

Jan 18

Here's Why We're Not Too Worried About SynAct Pharma's (NGM:SYNACT) Cash Burn Situation

Sep 03

SynAct Pharma (NGM:SYNACT) Is In A Good Position To Deliver On Growth Plans

Apr 07

Companies Like SynAct Pharma (NGM:SYNACT) Are In A Position To Invest In Growth

Dec 23

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jeppe Ovlesen en comparación con los beneficios de SynAct Pharma?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-kr216m
Sep 30 2023	n/a	n/a	-kr156m
Jun 30 2023	n/a	n/a	-kr148m
Mar 31 2023	n/a	n/a	-kr129m
Dec 31 2022	kr4m	kr3m	-kr99m
Sep 30 2022	n/a	n/a	-kr95m
Jun 30 2022	n/a	n/a	-kr89m
Mar 31 2022	n/a	n/a	-kr78m
Dec 31 2021	kr2m	kr2m	-kr69m
Sep 30 2021	n/a	n/a	-kr52m
Jun 30 2021	n/a	n/a	-kr41m
Mar 31 2021	n/a	n/a	-kr35m
Dec 31 2020	kr2m	kr2m	-kr27m
Sep 30 2020	n/a	n/a	-kr29m
Jun 30 2020	n/a	n/a	-kr24m
Mar 31 2020	n/a	n/a	-kr23m
Dec 31 2019	kr2m	kr2m	-kr24m
Sep 30 2019	n/a	n/a	-kr20m
Jun 30 2019	n/a	n/a	-kr23m
Mar 31 2019	n/a	n/a	-kr24m
Dec 31 2018	kr2m	kr2m	-kr23m
Sep 30 2018	n/a	n/a	-kr23m
Jun 30 2018	n/a	n/a	-kr19m
Mar 31 2018	n/a	n/a	-kr15m
Dec 31 2017	kr2m	kr2m	-kr15m

Compensación vs. Mercado: La compensación total de Jeppe($USD335.81K) está por encima de la media de empresas de tamaño similar en el mercado Swedish ($USD238.31K).

Compensación vs. Ingresos: La compensación de Jeppe ha aumentado mientras la empresa no es rentable.

CEO

Jeppe Ovlesen (61 yo)

less than a year

Permanencia

kr3,656,000

Compensación

Mr. Jeppe Ovli Ovlesen, EE, MBA, serves CEO & Director of SynAct Pharma AB since March 20, 2024. He serves as Director at Cereno Scientific AB (publ) since November 07, 2023. He served as the Chief Execut...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jeppe Ovlesen	CEO & Director	less than a year	kr3.66m	0.033% SEK 96.8k
Bjorn Westberg	Chief Financial Officer	less than a year	sin datos	sin datos
Thomas Boesen	Chief Operating Officer	3.3yrs	sin datos	0.045% SEK 130.2k
James Knight	Chief Business Officer	3.3yrs	sin datos	sin datos
Kristen Harting	Chief Medical Officer	less than a year	sin datos	sin datos

0.9yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de SYNACT no se considera experimentado ( 0.8 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jeppe Ovlesen	CEO & Director	less than a year	kr3.66m	0.033% SEK 96.8k
Sten Scheibye	Director	less than a year	sin datos	sin datos
Vibeke Strand	Member of Clinical Advisory Board	less than a year	sin datos	sin datos
Mauro Perretti	Member of Scientific Advisory Board	no data	sin datos	sin datos
Anders Kronborg	Chairman of Board	less than a year	sin datos	sin datos
Sten Sorensen	Director	less than a year	sin datos	sin datos
Ravi Rao	Member of Clinical Advisory Board	less than a year	sin datos	sin datos
Roy Fleischmann	Member of Clinical Advisory Board	less than a year	sin datos	sin datos
Mauro Teixeira	Member of Scientific Advisory Board	no data	sin datos	sin datos

0.2yrs

Permanencia media

61yo

Promedio de edad

Junta con experiencia: La junta directiva de SYNACT no se considera experimentada (0.1 años de permanencia promedio), lo que sugiere una nueva junta directiva.

SynAct Pharma Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

Chief Operating Officer recently bought kr1.9m worth of stock

Chief Operating Officer recently sold kr145k worth of stock

SynAct Pharma AB Announces CEO Changes

SynAct Pharma AB (publ) Announces Resignation of Marina Bozilenko as Member of the Board of Directors

High number of new and inexperienced directors

Synact Pharma Appoints Kristen Harting as Chief Medical Officer, Effective 15 February 2024

Recent updates

Chief Operating Officer recently bought kr1.9m worth of stock

SynAct Pharma AB has completed a Follow-on Equity Offering in the amount of SEK 49.239162 million.

New major risk - Revenue and earnings growth

Chief Operating Officer recently sold kr145k worth of stock

SynAct Pharma AB has filed a Follow-on Equity Offering in the amount of SEK 45 million.

SynAct Pharma AB Announces CEO Changes

SynAct Pharma AB Announces Outcomes of the Independent Audit of the 4-Week Resolve P2a Clinical Trial in Rheumatoid Arthritis

SynAct Pharma AB (publ) Announces Resignation of Marina Bozilenko as Member of the Board of Directors

New major risk - Financial position

SynAct Pharma AB to Report Q3, 2024 Results on Oct 30, 2024

SynAct Pharma Announces Additional Data from the Expand P2b Clinical Trial Supporting Continued Development of the Compound in Rheumatoid Arthritis

SynAct Pharma AB to Report Q4, 2023 Results on Feb 23, 2024

High number of new and inexperienced directors

Synact Pharma Appoints Kristen Harting as Chief Medical Officer, Effective 15 February 2024

Synact Pharma Expands Its Rheumatology Clinical Advisory Board with Three New Highly Experienced Advisors

SynAct Pharma AB, Annual General Meeting, May 23, 2024

SynAct Pharma AB has completed a Follow-on Equity Offering in the amount of SEK 60.525 million.

SynAct Pharma AB Announces Evaluation of the 4-Week RESOLVE P2a Clinical Trial in Moderate to Severe Active Rheumatoid Arthritis Patients with an incomplete Response to Methotrexate

SynAct Pharma AB Announces Additional Data from the Expands P2b Clinical Trial Further Supporting Efficacy and Activity seen in Patients with Elevated CRP

SynAct Pharma AB Announces Additional Data from the EXPAND P2b Clinical Trial and Identifies Population with Responsiveness to Resomelagon

Synact Pharma Announces Top Line Data from the 12-Week Expand P2b Clinical Trial in Severe Active Newly Diagnosed Rheumatoid Arthritis Patients

SynAct Pharma AB (Publ) Completes Dosing in Part A of Combined Phase 2A/B Resomelagon (AP1189) in Rheumatoid Arthritis (RA)

SynAct Pharma AB (publ) Completes Patient Recruitment for Part A of Combined Phase 2a/b RESOLVE Study of Resomelagon (AP1189) in Rheumatoid Arthritis

SynAct Pharma AB (publ) Announces the Completion of Dosing in the Phase 2b Expand Study of Resomelagon (AP1189) in Early Severe Rheumatoid Arthritis Patients

Chief Operating Officer recently bought kr78k worth of stock

SynAct Pharma AB Announces Appointment of Thomas Von Koch as Board Member

SynAct Pharma AB Appoints Björn Westberg as Chief Financial Officer

SynAct Pharma AB to Report Q1, 2023 Results on May 05, 2023

SynAct Pharma AB (OM:SYNACT) completed the acquisition of TXP Pharma AG from Boesen Biotech ApS, GL Capital AB, TJ Biotech Holding ApS, Quantass ApS, and James Knight.

SynAct Pharma AB Announces Change in Nomination Committee Prior to Agm 2023

Chief Operating Officer recently sold kr3.4m worth of stock

SynAct Pharma AB (OM:SYNACT) entered into a conditional agreement to acquire TXP Pharma AG from Boesen Biotech Aps, Glcapital Ab, TJ Biotech Holding ApS, Quantass ApS, and James Knight for approximately SEK 190 million.

No independent directors

SynAct Pharma AB Receives IND Clearance from the FDA for Phase 2A/B Trial of Ap1189 in Ra

SynAct Pharma AB, Annual General Meeting, May 25, 2023

Synact Submits Ind and Recruits First Patient

Synact Pharma Submits IND for US Phase 2A/B Clinical Trial

SynAct Pharma AB (Publ) Enrolls First Patient in Phase 2b Trial of Ap1189 in RA

SynAct Pharma AB Announces Approval of Amended Study Protocol for the Phase 2A Study in iMN

Here's Why We're Watching SynAct Pharma's (STO:SYNACT) Cash Burn Situation

SynAct Pharma AB (publ) Announces That the Clinical Trial Application to Initiate the Clinical Phase 2B Study, Expand

SynAct Pharma AB Improves the Design of the Ongoing Phase 2A Study in Imn

SynAct Pharma AB Improves the Design of the Ongoing Phase 2A Study in Imn

Synact Pharma Receives pre-IND Response from the U.S. Food and Drug Administration

SynAct Pharma Submits CTA for Clinical Phase 2b Study in RA

John Haurum Declines Re-Election as Board Member of SynAct Pharma AB

SynAct Pharma AB Completes Clinical Pharmacokinetic Test of Ap1189 Tablet

No independent directors

Is SynAct Pharma (NGM:SYNACT) In A Good Position To Deliver On Growth Plans?

SynAct Pharma AB Announces Additional Data from the BEGIN Study

SynAct Pharma AB Reports Positive PK Data on AP1189 Tablets

SynAct Pharma AB Completes Patient Recruitment to the Phase 2A Begin Study of Ap1189 in Early Severe Rheumatoid Arthritis

Here's Why We're Not Too Worried About SynAct Pharma's (NGM:SYNACT) Cash Burn Situation

SynAct Pharma AB Provides an Update on Patient Recruitment in the Phase 2a Clinical Trial of AP1189 in Rheumatoid Arthritis

SynAct Pharma AB Announces Grant of Key European Patent Covering Ap1189

Chief Medical Officer Thierry Duvauchelle has left the company

Synact Pharma AB Announces Positive Data from A Phase 2A Trial of Ap1189 in Covid-19 Infected Patients

SynAct Pharma Files Patent Applications Related to AP1189 Derived APIs and Oral Formulations

SynAct Pharma Updates Phase II study with AP1189

Synact Pharma Expands Ap1189 Begin Study in Rheumatoid Arthritis Uk Version

SynAct Pharma (NGM:SYNACT) Is In A Good Position To Deliver On Growth Plans

SynAct Pharma AB Initiates Dosing in Part 2 of the Clinical Phase II Study with AP1189 in Covid-19 Infected Patients UK Version

Chief Financial Officer recently sold kr2.9m worth of stock

SynAct Pharma AB Names James Knight as Chief Business Officer

New 90-day high: kr61.00

SynAct Pharma AB Names Thomas Boesen as Chief Operating Officer

New 90-day high: kr51.00

Companies Like SynAct Pharma (NGM:SYNACT) Are In A Position To Invest In Growth

New 90-day low: kr34.20